We recently compiled a list of the 10 High Growth Healthcare Stocks to Invest in Now. In this article, we are going to take a ...
StockNews.com cut shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) from a buy rating to a hold rating in a ...
After about five years working behind the scenes, Arrakis Therapeutics is unveiling that its lead program will aim to treat ...
Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Alnylam Pharma (ALNY – Research Report), boosting the price target to ...
A patient in the UK has received a new therapy for Huntington’s disease, which experts hope could slow progression of the fatal illness. Huntington’s is an inherited condition that is caused by a ...
RBC Capital analyst Luca Issi maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) on November 25 and set a price target of ...
The FDA has accepted Alnylam’s supplemental New Drug Application for Amvuttra on the heels of BridgeBio’s Attruby nod, ...
GlobalData on MSN15d
Alnylam reveals trial outcomes of nucresiran for ATTR amyloidosis treatmentThe study showed significant reductions in serum TTR levels in subjects after a single dose, with sustained effects over time ...
The company reached a deal to divest its third biosimilar this year, selling a copycat version of Amgen’s Neulasta for up to ...
By collecting data from four different antenna orientations post-surgery, researchers are detecting significantly more detailed information on breast cancer than a traditional single-orientation scan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback